Pulse Biosciences (FRA:6L8) Accounts Payable & Accrued Expense : €2.02 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Pulse Biosciences Accounts Payable & Accrued Expense?

Pulse Biosciences's quarterly accounts payable & accrued expense increased from Sep. 2023 (€2.03 Mil) to Dec. 2023 (€2.25 Mil) but then declined from Dec. 2023 (€2.25 Mil) to Mar. 2024 (€2.02 Mil).

Pulse Biosciences's annual accounts payable & accrued expense declined from Dec. 2021 (€3.86 Mil) to Dec. 2022 (€2.64 Mil) and declined from Dec. 2022 (€2.64 Mil) to Dec. 2023 (€2.25 Mil).

Pulse Biosciences Accounts Payable & Accrued Expense Historical Data

The historical data trend for Pulse Biosciences's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulse Biosciences Accounts Payable & Accrued Expense Chart

Pulse Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

2.48

3.06

3.86

2.64

2.25

Pulse Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															3.40	2.32	2.03	2.25	2.02

Pulse Biosciences Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Pulse Biosciences (FRA:6L8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulse Biosciences Inc (FRA:6L8) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

PLSE:USA

Address

3957 Point Eden Way, Hayward, CA, USA, 94545

Website

https://www.pulsebiosciences.com

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.

Pulse Biosciences (FRA:6L8) Headlines

No Headlines